Girao Tiago 4

4 · CYTORI THERAPEUTICS, INC. · Filed Jul 27, 2018

Form 4

Period: 2018-07-25

VP & Chief Financial Officer

Transactions

Exercise of In-Money
Subscription Rights (Right to Buy)
2018-07-25−1→ 0 total
Exercise: $1000.00From: 2018-06-29Exp: 2018-07-20→ See Footnote
Exercise of In-Money
Warrants (Right to Buy)
2018-07-25+1,050→ 1,050 total
Exercise: $0.80Exp: 2021-01-25→ Common Stock (1,050 underlying)
Exercise of In-Money
Series C Preferred Stock
2018-07-25+1→ 1 total
Exercise: $0.80From: 2018-07-25→ Common Stock (1,253 underlying)

Footnotes (3)

[F1]The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, Inc. (the "Company") to all holders of the Company's common stock and Series B Preferred Stock on June 26, 2018. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series C Preferred stock (convertible into 1,253 of the Company's common stock) and 1,050 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000.
[F2]The Series C Preferred Stock has no expiration date.
[F3]Each warrant entitles the holder to purchase one share of the Company's common stock at an exercise price of $0.7986 through January 25, 2021.

Documents

1 file